Product Name: Obeticholic Acid CAS NO: 459789-99-2
Chemical & Physical Properties:
Appearance : White to off-white crystalline powder
Assay : ≥99.0%
Boiling Point: 562.9℃ at 760 mmHg
Flash Point: 308.3℃
Refractive Index: 1.529
Vapor Pressure: 0mmHg at 25°C
Solubility: Dioxane (Sparingly), DMSO (Slightly), Methanol (Slightly);
Category: Standards; Steroids; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites;
HS Code: 2918990090
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
1. 6α-ethyl-chenodeoxycholic acid has been known as INT-747. It is undergoing development as a pharmaceutical agent for several liver diseases and related disorders;
2. It is a derivative of the bile acid Chenodeoxycholic Acid.
Our factory manufacture’s Obeticholic Acid mature technology, stable output, quality assurance.
Inventory Status : In Stock.
We can provide 6-Ethylchenodeoxycholic aicd certificate of analysis( COA), CAS 459789-99-2 Method of Analysis (MOA), Route of synthesis (ROS), (3alpha,5beta,6alpha,7alpha)-6-Ethyl-3,7-dihydroxycholan-24-oic acid Material Safety Data Sheet (MSDS) and other support for you !
Obeticholic Acid also known as 6-ethylchenodeoxycholic acid, is a new derivative of chenodeoxycholic acid (CDCA) in human primary bile acids. It is a farnesoid derivative X receptor (FXR). ) Of natural ligands. Obeticholic acid is a farnesoid X receptor agonist, which indirectly inhibits the gene expression of cytochrome 7A1 (CYP7A1) by activating the farnesoid X receptor. Because CYP7A1 is the rate-limiting enzyme of bile acid biosynthesis, obeticholic acid can inhibit bile acid synthesis and is used to treat primary biliary cirrhosis and non-alcoholic fatty liver disease.
Obeticholic acid was successfully developed by Intercept Pharmaceuticals in the United States. It is the first drug developed for the treatment of cholestatic liver disease in 20 years. The study is for patients who do not adequately respond or cannot tolerate the old standard treatment drug ursodeoxycholic acid.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.